EP0202062A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Quinuclidine derivatives
Assignee: Beecham Group PLC
•
Filing: 1986-05-06
•
Granted: —
•
Expires: 2006-05-06
Abstract
Abstract Compounds of formula (I), and pharmaceutically acceptable salts thereof: <CHEM> wherein R1 is C1-6 alkyl; R2 is amino, C1-7 acylamino or methyl; R3 is halo or C1-6 alkylthio; R4 and R5 are independently selected from hydrogen, C1-6 alkyl, phenyl or phenyl C1-4 alkyl any of which phenyl moieties may be substituted by one or two of halo, CF3, C1-6 alkoxy or C1-6 alkyl; and n is 1 to 3 having gastric motility enchancing activity, a process for their preparation and their use as pharmaceuticals.
Inventors
- 👤 Francis David King
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 21:04
CPC Classifications
C; C07; C07D; C07D453/00; C07D453/02; A; A61; A61P; A61P1/00; A61P1/08
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
83 words
A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein: R1 is C 1-6 alkyl; R 2 is amino, C 1-7 acylamino or methyl; R 3 is halo or C 1-6 alkylthio; R 4 and R 5 are independently selected from hydrogen, C 1-6 alkyl, phenyl or phenyl C 1-4 alkyl any of which phenyl moieties may be substituted by one or two of halo, CF 3 , C 1-6 alkoxy or C 1-6 alkyl; and n is 1 to 3.
Claim 2
Dependent Claim
83 words
A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein: R1 is C 1-6 alkyl; R 2 is amino, C 1-7 acylamino or methyl; R 3 is halo or C 1-6 alkylthio; R 4 and R 5 are independently selected from hydrogen, C 1-6 alkyl, phenyl or phenyl C 1-4 alkyl any of which phenyl moieties may be substituted by one or two of halo, CF 3 , C 1-6 alkoxy or C 1-6 alkyl; and n is 1 to 3.
Claim 3
Dependent Claim
13 words
2 . A compound according to claim 1 wherein R 1 is methyl.
Claim 4
Dependent Claim
17 words
3 . A compound according to claim 1 or 2 wherein R 3 is chloro or bromo.
Claim 5
Dependent Claim
14 words
A compound according to claim 1, 2 or 3 wherein R 5 is hydrogen.
Claim 6
Dependent Claim
35 words
A compound according to claim 1 of formula (II): wherein R 6 is hydrogen or acetyl; R 4 1 is hydrogen or C l - 6 alkyl; and n is as defined in claim 1.
Claim 7
Dependent Claim
15 words
A compound according to any one of claims 1 to 5 wherein n is 2.
Claim 8
Dependent Claim
3 words
4-Amino-5-chloro-2-methoxy-N - (4-quinuclidinyl)-benzamide.
Claim 9
Dependent Claim
3 words
4-Amino-5-chloro-2-methoxy-N - (4-quinuclidinyl)-benzamide.
Claim 10
Dependent Claim
69 words
A process for the preparation of a compound of formula (I) as defined in claim 1, which process comprises reacting a compound of formula (III): with a compound of formula (IV): wherein Q is a leaving group; R 7 is R 2 or nitro; and the remaining variables are as defined in claim 1, and thereafter optionally converting R 7 to R 2 ahd/or forming a pharmaceutically acceptable salt.
Claim 11
Dependent Claim
26 words
A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
25 words
A compound according to any one of claims 1 to 7 for use in the treatment of disorders relating to impaired gastro-intestinal motility and/or emesis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.